Pentadecapeptide BPC 157 and the central nervous system.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical animal studies with no human data
PubMed 34380875 · doi:10.4103/1673-5374.320969
What was done
This narrative review synthesized preclinical findings on the effects of the synthetic gastric peptide BPC 157 across various rat models of central nervous system disorders. The reviewed experimental models included bilateral common carotid artery clamping-induced stroke during reperfusion, drug-induced catalepsy and schizophrenia-like behavioral phenotypes (using L-NAME, haloperidol, amphetamine, apomorphine, MK-801, and methamphetamine), and mechanical spinal cord compression.
What was found
No numerical values, effect estimates, or sample sizes are reported in the abstract. BPC 157 treatment was described as reducing stroke-induced neuronal damage, improving memory, locomotion, and coordination, and modulating hippocampal gene expression. It reportedly counteracted drug-induced catalepsy and positive-like schizophrenia symptoms by interacting with nitric oxide and dopamine systems, and promoted functional recovery (mitigating tail paralysis), nerve recovery, and vascular restoration following spinal cord compression in rats.
Why it matters
The paper summarizes mechanistic and behavioral evidence in rodents suggesting BPC 157 may exert neuroprotective, vasoactive, and neuromodulatory effects across diverse central nervous system injury models.
Limits
The findings are exclusively from animal (rodent) models, meaning efficacy, safety, and pharmacokinetics in humans remain unestablished. The abstract provides no quantitative data, and the publication is a non-systematic narrative review without standardized quality or bias assessments.
Cited by
- supports Numerous animal studies on peptide BPC-157 demonstrate accelerated cartilage repair, nerve regeneration, and angiogenesis.